At a Glance
| BPC-157 | Tirzepatide | |
|---|---|---|
| Class | Peptide | Peptide hormone |
| Common Dose (subcutaneous injection) | 250–500 mcg | 5–10 mg |
| Total Duration | 0 hrs | 2.3–9 hrs |
| Routes | Subcutaneous InjectionOral | Subcutaneous injection |
BPC-157, a Peptide, and Tirzepatide, a Peptide hormone, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. BPC-157 is classified as a Peptide while Tirzepatide is a Peptide hormone, meaning they approach altered states through different pharmacological mechanisms. They share 1 documented effects in common, with 5 effects unique to BPC-157 and 4 unique to Tirzepatide. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| BPC-157 | Tirzepatide | |
|---|---|---|
| Class | Peptide | Peptide hormone |
| Common Dose (subcutaneous injection) | 250–500 mcg | 5–10 mg |
| Total Duration | 0 hrs | 2.3–9 hrs |
| Routes | Subcutaneous InjectionOral | Subcutaneous injection |
| Effects | 6 documented | 5 documented |
| Level | BPC-157 | Tirzepatide |
|---|---|---|
| Threshold | 50 mcg | 2.5 mg |
| Light | 100–200 mcg | 2.5–5 mg |
| Common | 250–500 mcg | 5–10 mg |
| Strong | 500–750 mcg | 10–15 mg |
| Heavy | 1000 mcg | 15 mg |
| Level | Dose |
|---|---|
| Threshold | 100 mcg |
| Light | 200–500 mcg |
| Common | 500–1000 mcg |
| Strong | 1000–1500 mcg |
| Heavy | 2000 mcg |
BPC-157
Tirzepatide
No direct interaction data available between these substances. This does not mean the combination is safe.
No dangerous interactions recorded.
No dangerous interactions recorded.